NCT00766246终止2 期
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Pharmatech
- 入组人数
- 125
- 主要终点
- Progression-free survival (PFS) of bevacizumab and pemetrexed compared to pemetrexed monotherapy during second-line treatment of Stage IIIB or IV NSCLC
研究概览
简要总结
This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).
详细描述
This phase II clinical trial will address the issues of bevacizumab treatment duration and treatment safety as first-line therapy for patients with non-squamous NSCLC. Following disease progression or treatment failure, the potential benefit of continued bevacizumab therapy will be tested by randomizing patients to two treatment arms, including second-line chemotherapy with or without further bevacizumab. It is hypothesized that continuation of bevacizumab with pemetrexed as second-line treatment following progression will result in improved clinical outcomes for patients with NSCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Histologically or cytologically confirmed stage IIIB with malignant pleural effusion or stage IV NSCLC except squamous-cell carcinoma
- •Measurable disease defined by RECIST
- •Adequate organ function:
- •Absolute neutrophil count ≥ 1.5 x 10(9)/L
- •Hemoglobin ≥ 9.0 g/dL
- •Platelets ≥ 100 x 10(9)/L
- •Hepatic enzyme levels: AST and ALT and Alkaline Phosphatase must be within range allowing for eligibility. In determining eligibility, the more abnormal of the two values (AST or ALT) should be used according to table listed in the protocol
- •Bilirubin ≤ ULN
- •Serum Creatinine ≤ 1.5 mg/dL (or creatinine clearance ≥ 60mL/min)
- •Urine protein/creatinine ratio < 1.0 OR urine dipstick for proteinuria < 2 + (patients discovered to have ≥ 2 + proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤1g of protein in 24 hours to be eligible)
- •ECOG Performance Status 0-1
- •Estimated survival of ≥ 12 weeks
- •Provide written informed consent
排除标准
- •Prior chemotherapy for advanced NSCLC
- •Neoadjuvant or adjuvant treatment within six (6) months of registration
- •Prior radiation therapy within three (3) weeks of registration; all side effects must have resolved by registration
- •Prior treatment with an investigational or marketed agent that acts by antiangiogenesis mechanisms
- •Large ( > 4 cm) centrally located lesions or large lesions in close proximity to major blood vessels unless treated with palliative radiation
- •Brain metastases or leptomeningeal disease, except for patients who have had a resection and/or completed a course of cranial irradiation, have no worsening CNS symptoms, and have discontinued all corticosteroids for that indication for at least one (1) month prior to registration
- •History of gross hemoptysis (defined as bright red blood of at least ½ teaspoon or 2.5 mL per episode) within three (3) months of registration unless definitively treated with surgery, radiation, arteriographic embolization, or endobronchial interventions at least four (4) weeks prior to registration
- •Presence of cavitory lesion
- •Presence of squamous histology (mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; sputum cytology alone is not acceptable)
- •Peripheral neuropathy > grade 1
- •Major surgery, open biopsy or significant traumatic injury within four (4) weeks of registration or anticipation of need for major surgical procedure during the course of the study
- •Minor surgical procedures, fine needle aspirations or core biopsies within one (1) week prior to registration
- •Current, ongoing therapeutic anticoagulation with full-dose warfarin or its equivalent
- •Current or recent (within ten [10] days of the first dose of study treatment) use of aspirin (at least 325 mg/day) or other NSAIDs with anti-platelet activity or treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), or cilostazol (Pletal)
- •History of prior malignancy within the past three (3) years except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or treated localized prostate cancer with a current PSA of < 1.0 mg/dL on two successive evaluations, at least three (3) months apart, with the most recent evaluation no more than four (4) weeks prior to registration
- •History of serious systemic disease including:
- •Unstable angina, New York Heart Association (NYHA) ≥ Grade II or congestive heart failure
- •Inadequately controlled hypertension (blood pressure >150/100 mmHg while taking antihypertensive medications)
- •Unstable symptomatic arrhythmia requiring medication
- •Myocardial infarction within six (6) months prior to registration
- •Stroke within six (6) months prior to registration
- •Transient ischemic attack within six (6) months prior to registration
- •Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within six (6) months prior to registration
- •Clinically significant peripheral vascular disease or evidence of bleeding, diathesis (prone to bleeding) or coagulopathy
- •Active systemic bacterial, fungal or viral infection, including known HCV and HIV
- •Pregnancy or women who are breast-feeding; women of child-bearing potential and non-vasectomized men must agree to use effective methods of birth control during and three (3) months following treatment period and women of child-bearing potential must have a negative pregnancy test
- •History of severe hypersensitivity reaction to docetaxel or any other drugs formulated with polysorbate 80
- •Any other medical condition, including mental illness or substance abuse, which in the judgment of the investigator, is likely to interfere with a patient's ability to provide informed consent, cooperate, and participate in the study, or to interfere with the interpretation of the results
- •Use of any investigational agent within four (4) weeks prior to registration
研究组 & 干预措施
First-line
Experimental
Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
干预措施: bevacizumab (Drug)
First-line
Experimental
Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
干预措施: docetaxel (Drug)
First-line
Experimental
Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
干预措施: carboplatin (Drug)
Maintenance
Experimental
Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
干预措施: bevacizumab (Drug)
结局指标
主要结局
Progression-free survival (PFS) of bevacizumab and pemetrexed compared to pemetrexed monotherapy during second-line treatment of Stage IIIB or IV NSCLC
时间窗: Duration of study
次要结局
- Objective tumor response (objective response rate [ORR]) in first-line and maintenance treatment(Duration of the study)
- Treatment safety in first-line, maintenance and second-line treatment(Duration of the study)
- Overall Survival (OS)(Duration of the study)
- Objective tumor response (objective response rate [ORR]) in second-line treatment(Duration of the study)
- Progression-free survival (PFS) in first-line and maintenance treatment(Duration of the study)
研究者
相似试验
已完成
2 期
Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior TherapySquamous Cell Carcinoma of the EsophagusNCT03762564Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest21
招募中
2 期
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT06558227Suzhou Zelgen Biopharmaceuticals Co.,Ltd90
终止
2 期
Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar CholangiocarcinomaHilar CholangiocarcinomaNCT02955771Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.7
已完成
1 期
Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib CapsuleBioequivalenceNCT04768985AstraZeneca66
招募中
2 期
Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal CancerColo-rectal CancerNCT04296019Shanghai Zhongshan Hospital110